Health Care·Pharmaceuticals·$6.1B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.43 | N/A | +46.58% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.43 | N/A | +46.58% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management acknowledged the difficulties faced in the quarter. They remain focused on their strategic goals but did not provide specific guidance.
Management highlighted ongoing challenges in the current market environment.
They expressed commitment to long-term strategies despite short-term setbacks.
The earnings report indicates that Terns Pharmaceutical is still facing challenges, particularly reflected in their EPS results. The stock's 11.01% decline suggests that investors are reacting negatively to the lack of revenue data and guidance. The surprise in EPS may indicate some operational improvements, but overall uncertainty remains a concern for investors.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
FABRINET
Aug 16, 2021